Release No 38/2009 Affitech Issues Update on Litigation Copenhagen and Oslo, December 29th, 2009 Affitech A/S, (Nasdaq OMX: AFFI), the antibody medicines company, today announced that the ongoing litigation with a minority group of shareholders has been resumed in the Lyngby court, as requested by Affitech, following an action from the plaintiffs for an early ruling against the Company. The Company expects the court to now consider Affitech's response to the plaintiffs' claims. As stated previously in the Company's June 30th prospectus document, Affitech continues to believe that there is no legal basis for the objections filed in the minority shareholders' writ and the Company intends to defend its position vigorously. For more information please contact: Affitech: Robert F Burns, PhD CEO Tel # +45 50 99 76 42 About Affitech Affitech AS is a publically traded (Nasdaq OMX Copenhagen exchange) human therapeutic antibody company headquartered in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech's premier discovery engine for the isolation of lead antibodies to cell surface molecules in situ. Several of the Company's proprietary product candidates were generated by CBAS™. Further information is available at www.affitech.com.